PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, and portfolio company of Partners Group, announced on Monday the signing of a definitive agreement for the acquisition of majority stake in the company by Kohlberg & Company (Kohlberg).

Kohlberg is a leading private equity firm headquartered in Mount Kisco, New York with over 30 years of successful experience partnering with management and companies similar to PCI Pharma Services.

Mubadala Investment Company (Mubadala), will also become a significant investor in PCI.

Partners Group, the global private markets investment manager, has agreed the sale of its majority equity stake in PCI Pharma Services on behalf of its clients and alongside its consortium partners Thomas H. Lee Partners and Frazier Healthcare Partners.

Following the sale, to private equity firm Kohlberg and Mubadala, Partners Group will retain a meaningful minority equity stake in the Company. The terms of the transaction are not disclosed.

“PCI teams have embarked on a purposeful journey over recent years to transform the company by executing a successful growth strategy providing customers with innovative and integrated supply chain solutions with the industry-leading customer experience by differentiating through investment in global capabilities, operational excellence, technology and our biggest asset, our talented people”, said Salim Haffar, PCI’s CEO.

“Kohlberg brings considerable successful experience in the biopharmaceuticals and medical device areas, and I am thrilled to be continuing with them to accelerate the growth of our commercial, clinical trial services, and development manufacturing businesses under this new alliance,” he added.

WAM